BIOTECH CATALYST AI SCANNER — July WK3

This week's screen is dominated by a late-July-through-August PDUFA pileup — nine of ten featured names have FDA decisions or major data landing inside the next six weeks, and five of those cluster in a five-day stretch between July 26 and August 5. That's an unusually dense binary-event calendar even for biotech, and it spans the full spectrum from Moderna's mega-cap flu vaccine filing down to Outlook Therapeutics trading at $1.45 with three prior rejections behind it.

The subplot running underneath the regulatory calendar is corporate: Lantheus is fielding a roughly $7 billion takeover approach from Curium while it awaits its own PDUFA date, MannKind is digesting last October's scPharmaceuticals acquisition into a new filing, and Capricor is simultaneously suing its own commercial partner. Alzheimer's diagnostics and therapeutics both show up this week too — Biogen's at-home Leqembi injection and Lantheus's tau PET tracer are effectively two sides of the same disease, filed months apart.

What We're Tracking:

Trading Below Cash: None this week
Cash Pressure: RARE, BIIB, OTLK
Initial Data: None
Multi-Catalyst: None

#1. MRNA — Moderna Inc.

THE CATALYST
Event: mRNA-1010 (P304) — PDUFA Regulatory Decision in seasonal influenza, U.S. adults 50 and older
Date: Aug 05, 2026
BSI: 7.65/10

Moderna's mRNA-1010 BLA got a refusal-to-file letter in February — the FDA wanted more before it would even review it — then cleared VRBPAC 9-0 on benefit-risk four months later, an unusually fast turnaround for a first-in-class filing. The company's core business is mRNA vaccines and therapeutics, anchored by a Merck partnership on the personalized cancer vaccine mRNA-4157, plus recent European approvals for combination flu-COVID and RSV shots as it manages post-pandemic revenue normalization.

📈 The Setup: mRNA-1010 packages hemagglutinin antigens from four seasonal flu strains into lipid nanoparticles (fatty spheres that ferry genetic instructions into cells) — the same delivery platform behind Moderna's COVID shots, applied to a market still dominated by egg- and cell-based manufacturing. In the pivotal P304 trial (~40,700 adults 50+), a single dose beat standard-dose inactivated vaccine by 26.6% relative efficacy against confirmed flu, with consistent strain-level results (H1N1 29.6%, H3N2 22.2%, B/Victoria 29.1%) and higher antibody titers than both standard-dose and high-dose comparators. Fluzone HD and Fluad are the enhanced options patients currently get; mRNA-1010 would be the first mRNA product to clear that bar. Shares are pricing in approval odds after the 9-0 VRBPAC vote, but the market hasn't fully credited the manufacturing-flexibility edge mRNA production has over conventional egg-based lines heading into a seasonal launch.

✅ The Edge: Only mRNA candidate with an active BLA under FDA review for seasonal flu — no rival mRNA program is at comparable regulatory stage. The 9-0 VRBPAC vote after a prior refusal-to-file shows the data package cleared the agency's highest bar for a first-in-class filing.

⚠️ The Risk: Seasonal manufacturing has to scale fast enough to supply 2026-2027 volumes without the fill-finish delays that have dogged prior mRNA launches, and Fluzone HD and Fluad already have physician habit and premium reimbursement on their side — ACIP recommendations and real-world data will decide whether that habit breaks.

#2. NRXP — NRX Pharmaceuticals Inc.

THE CATALYST
Event: KETAFREE — GDUFA Regulatory Decision for a preservative-free IV ketamine formulation
Date: Jul 29, 2026
BSI: 6.86/10

NRx's generic IV ketamine ANDA cleared FDA's bioequivalence review with no deficiencies flagged, and follow-up quality letters asked only for administrative fixes — about as clean a pre-approval signal as a generic filing gets. The company's core focus is neuroplastic therapies for depression, PTSD, and autism, delivered partly through its own HOPE Therapeutics clinics (TMS, hyperbaric oxygen), expanded via a January 2026 tie-up with neurocare Group AG. A separate branded ketamine program, NRX-100, sits alongside KETAFREE in the pipeline.

📈 The Setup: KETAFREE is a straightforward bioequivalence play: same racemic ketamine molecule already used in anesthesia and pain management, reformulated as a single-patient, preservative-free vial instead of the multidose vials that rely on benzethonium chloride — a preservative the FDA no longer recognizes as safe. This isn't a new molecule, it's a manufacturing and safety upgrade to an existing generic. The March 17 letter from FDA's Bioequivalence Program found no deficiencies, and subsequent Discipline Review Letters asked only for administrative changes — about as clean a runway to a GDUFA date as a generic gets. Spravato (esketamine nasal spray) owns the branded treatment-resistant-depression indication, but KETAFREE isn't competing there; it's targeting the roughly $750 million U.S. IV ketamine market currently served by those flagged multidose vials, with 1 million doses already scaled ahead of approval.

✅ The Edge: First preservative-free, single-patient IV ketamine positioned against multidose vials the FDA no longer considers safely preserved. The March 17 bioequivalence letter found zero deficiencies — a rare clean signal heading into a GDUFA date — and manufacturing is already scaled to 1 million doses.

⚠️ The Risk: This is a generic reformulation, not a new therapy — pricing pressure from existing compounded and multidose ketamine, plus Spravato's entrenched TRD franchise, could cap upside even with approval. Scaling single-patient vial manufacturing to commercial volume is also unproven at this size.

#3. CAPR — Capricor Therapeutics Inc.

THE CATALYST
Event: Deramiocel (CAP-1002, HOPE-2/HOPE-3) — PDUFA Regulatory Decision in Duchenne Muscular Dystrophy
Date: Jul 29, 2026
FDA Status: ODD
BSI: 6.80/10

After last July's CRL, the FDA asked for Capricor's full HOPE-3 clinical study report, got it, and converted the resubmission to Class 2 review — an Ad Com is now set for July 29, PDUFA for August 22. The company develops cell and exosome therapeutics for rare disease, with Duchenne muscular dystrophy as its lead program. It's also suing its own commercial partner, Nippon Shinyaku/NS Pharma, to rescind their U.S. distribution deal over a pricing flaw it says would block insured patient access.

📈 The Setup: Deramiocel is made of allogeneic cardiosphere-derived cells (donor heart-tissue progenitor cells with immunomodulatory and anti-fibrotic effects) — a different mechanism than the exon-skipping and gene-therapy approaches that dominate DMD, which restore dystrophin but don't directly address the fibrosis and inflammation driving decline. Three-year HOPE-2 extension data showed a 3.46-point decline on the upper-limb function scale versus 7.19 points in an external natural-history comparator, a 52% slowing (p=0.019), with parallel cardiac stabilization; five-year data presented in June 2026 held up. Sarepta's Elevidys, the only approved DMD gene therapy, has faced real uptake and safety scrutiny since launch — Deramiocel's pitch is that it addresses both skeletal and cardiac decline where Elevidys largely doesn't. At a ~$1.3B market cap, shares are pricing in another regulatory setback despite the FDA lifting the CRL and taking the full HOPE-3 package under Class 2 review.

✅ The Edge: Only late-stage cell therapy in DMD addressing both skeletal and cardiac decline — gene and exon-skipping rivals target dystrophin restoration alone. RMAT and Rare Pediatric Disease designations mean approval could also generate a sellable priority review voucher.

⚠️ The Risk: The prior CRL centered on data sufficiency, and FDA's track record with external-control comparators in DMD is mixed — a narrow, cardiomyopathy-only label is a real possibility. Even a clean approval doesn't resolve the ongoing lawsuit against NS Pharma, which could delay launch and payer contracting.

#4. FDMT — 4D Molecular Therapeutics Inc.

THE CATALYST
Event: 4D-150 (PRISM) — Conference Presentation in wet age-related macular degeneration
Date: Jul 18, 2026
FDA Status: RMAT
BSI: 6.76/10

The July 18 data isn't another interim look — it's the 2-year readout from the recently-diagnosed wet AMD subgroup that most closely mirrors 4FRONT-1's Phase 3 population, making it a direct read-through to pivotal expectations. 4D Molecular focuses on genetic medicines for eye disease, with secondary pulmonology and cardiology programs, and licenses 4D-150 to Otsuka for Asia-Pacific rights. 4FRONT-1 enrollment is already complete, and the FDA has granted 4D-150 RMAT designation.

📈 The Setup: 4D-150 is a single intravitreal injection using an evolved AAV capsid (a re-engineered viral shell, R100, that improves eye-tissue targeting) to make the eye produce its own aflibercept plus a VEGF-C-targeting RNAi — turning the retina into a standing anti-VEGF factory instead of requiring repeat injections. In the Phase 2b population-extension cohort, the high dose delivered 57% injection-free rates at 52 weeks with stable vision and no drug-related serious adverse events through 3.5 years — durability data that's held up longer than most gene-therapy rivals have reported. Adverum's ixo-vec and EyePoint's Duravyu implant are the closest Phase 3 competitors, but neither has matched this injection-free rate. Shares already carry an overbought RSI near 80 heading into July 18, so the market has priced in a good outcome — the open question is whether the recently-diagnosed subgroup data holds up as cleanly as prior cohorts.

✅ The Edge: 57% injection-free at one year with zero drug-related serious adverse events through 3.5 years — durability data ahead of Adverum's ixo-vec and EyePoint's Duravyu, the two closest Phase 3 rivals in intravitreal gene therapy for wet AMD.

⚠️ The Risk: This is a conference presentation, not a pivotal readout — 4FRONT-1 topline is still the real catalyst. The broader, more heterogeneous Phase 2b population could also show more response variability than the tighter Phase 3 cohort will.

#5. RARE — Ultragenyx Pharmaceutical Inc.

THE CATALYST
Event: DTX401 AAV gene therapy (pariglasgene brecaparvovec) — PDUFA Regulatory Decision in Glycogen Storage Disease Type Ia
Date: Aug 23, 2026
BSI: 6.47/10

DTX401 heads into its August 23 PDUFA with a clean regulatory history — Priority Review, no CRL — a contrast to Ultragenyx's UX111 program, which took its own CMC-related CRL last July on a separate resubmission track. Ultragenyx develops therapies for rare and ultra-rare genetic disease, concentrated in AAV gene therapy, with several late-stage assets running in parallel including UX111 and GTX-102.

📈 The Setup: DTX401 is a single IV infusion of an AAV8 vector (a re-engineered virus shell used to ferry a working gene into liver cells) carrying a functional copy of G6PC, the enzyme GSDIa patients lack, aiming to end a lifelong regimen of round-the-clock cornstarch dosing. Phase 1/2 data in 12 adults showed a 68% reduction in daily cornstarch intake at week 52; the placebo-controlled Phase 3 GlucoGene trial (52 patients total, up to six years follow-up) confirmed meaningful cornstarch reduction, maintained hypoglycemia control, and better quality-of-life scores with acceptable safety. No approved therapy addresses the underlying enzyme deficiency today — patients manage on cornstarch alone — so DTX401 would be first-in-class if cleared. Priority Review with no scheduled Ad Com points to a clean regulatory path, though the market is still pricing in some caution given Ultragenyx's UX111 program hit its own manufacturing-related CRL last year on a different asset.

✅ The Edge: First disease-modifying therapy in a disease where cornstarch dosing is the only option today. Priority Review with no Ad Com scheduled signals FDA isn't flagging major open questions heading into the August 23 date.

⚠️ The Risk: The full efficacy package still rests on just 52 patients, thin for a first-in-class approval. Ultragenyx's own UX111 program took a CMC-related CRL last year, a reminder that gene-therapy manufacturing scrutiny at the FDA remains high even on clean-looking filings.

#6. MNKD — MannKind Corporation

THE CATALYST
Event: FUROSCIX ReadyFlow Autoinjector (SCP-111) — PDUFA Regulatory Decision in edema, chronic heart failure and chronic kidney disease
Date: Jul 26, 2026
BSI: 6.44/10

MannKind's sNDA for the FUROSCIX autoinjector rests on a single Phase 1 study — a healthy-volunteer PK crossover showing the new 10-second delivery matches IV-level bioavailability, with no dedicated efficacy data in CHF or CKD patients. The company spans cardiometabolic and orphan lung disease, anchored by inhaled insulin Afrezza and the FUROSCIX subcutaneous diuretic franchise picked up in the October 2025 scPharmaceuticals acquisition. It also partners with United Therapeutics on dry-powder formulations using its Technosphere platform.

📈 The Setup: FUROSCIX already has an approved delivery method — a five-hour wearable on-body infusor pushing subcutaneous furosemide (a loop diuretic that blocks salt reabsorption in the kidney, pulling fluid out of the body) as an outpatient alternative to IV diuresis, which otherwise requires hospitalization. The ReadyFlow autoinjector compresses that same drug delivery into under 10 seconds. The bioavailability data — 107.3% relative to IV furosemide in a 45-to-80-year-old crossover cohort — supports IV-like exposure, but it's a healthy-volunteer study, not a CHF or CKD efficacy trial. Oral loop diuretics remain the default at home; the real question is whether shaving hours off administration time pulls more patients out of the hospital and onto FUROSCIX specifically, beyond what the existing infusor already captured since the scPharmaceuticals deal closed.

✅ The Edge: Only subcutaneous autoinjector formulation of a loop diuretic in the U.S. market — the on-body infusor version is already commercial, so ReadyFlow adds a faster format to an existing franchise rather than starting from zero.

⚠️ The Risk: The entire filing leans on one healthy-volunteer PK study — no CHF or CKD patient data specific to the autoinjector. If FDA wants device-specific safety data before approving a 10-second delivery mechanism, that's a CRL, not a delay.

#7. BIIB — Biogen Inc.

THE CATALYST
Event: LEQEMBI IQLIK (lecanemab-irmb, at-home injection) — PDUFA Regulatory Decision in early Alzheimer's disease
Date: Aug 24, 2026
BSI: 6.17/10

The sBLA under review isn't just a subcutaneous option — it specifically asks for SC dosing from the very first injection, not just maintenance, which would make Leqembi the only anti-amyloid therapy offering an at-home starter regimen. Biogen co-develops and co-promotes lecanemab with Eisai, which leads global regulatory submissions, and has redirected resources here since discontinuing Aduhelm. The company is building a new Kendall Square headquarters set to open in 2028.

📈 The Setup: Lecanemab is a monoclonal antibody (a lab-made protein designed to bind one specific target) that clears soluble aggregated amyloid-beta protofibrils, the toxic amyloid clumps thought to drive early Alzheimer's decline. In the pivotal Clarity AD trial (N=1,795), biweekly IV dosing slowed clinical decline on a standard dementia rating scale by 27% versus placebo at 18 months and reduced amyloid on PET imaging. Open-label extension data now show the weekly 360mg subcutaneous autoinjector delivers comparable drug exposure — the basis for this sBLA. Eli Lilly's donanemab (Kisunla) is the only other approved anti-amyloid antibody, but it's IV-only and dosed on a fixed course; an at-home SC starter regimen would be a real convenience edge in a category where efficacy between the two drugs otherwise looks similar. The August 24 PDUFA is binary: approval resets the competitive bar on convenience, a rejection leaves donanemab's IV regimen as the only option.

✅ The Edge: Would be the only anti-amyloid antibody offering subcutaneous dosing from day one — donanemab remains IV-only. That convenience gap matters in a category where efficacy between the two drugs is otherwise comparable.

⚠️ The Risk: Weekly SC dosing means higher initial drug exposure than the IV regimen, and FDA has scrutinized ARIA (amyloid-related brain swelling/microbleeds) closely across this drug class — any signal here could mean added monitoring requirements even with priority review.

#8. ALPMY — Astellas Pharma Inc. ADR

*JPY converted to USD— see note at bottom of article.

THE CATALYST
Event: KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), KEYNOTE-B15/EV-304 — PDUFA Priority Review in muscle-invasive bladder cancer
Date: Aug 17, 2026
BSI: 6.13/10

EV-304 is the first trial in nearly 25 years to show a non-platinum perioperative regimen beating cisplatin-based chemotherapy on both event-free and overall survival in muscle-invasive bladder cancer. Astellas is a Tokyo-headquartered oncology and urology company trading in the U.S. as an ADR (a foreign company's shares repackaged for U.S. exchanges), co-developing Padcev (enfortumab vedotin) with Pfizer and combination regimens with Merck's pembrolizumab. The combo already won approval for cisplatin-ineligible patients in November 2025; a parallel Japan filing for the cisplatin-eligible population followed in May 2026.

📈 The Setup: Enfortumab vedotin is an antibody-drug conjugate (a lab-made antibody wired to a cell-killing payload) targeting Nectin-4, a protein on bladder tumor cells; paired with pembrolizumab, a PD-1 checkpoint inhibitor, the combination is now seeking to replace neoadjuvant gemcitabine-cisplatin chemotherapy, the 25-year standard before bladder-removal surgery. In KEYNOTE-B15/EV-304, the combination cut the risk of an event-free-survival event by 47% and the risk of death by 35% versus chemotherapy — the first regimen in a quarter-century to beat that benchmark on both endpoints, per data presented at ASCO GU 2026. The combo already has approval for cisplatin-ineligible patients from November 2025; this PDUFA would extend it to the larger cisplatin-eligible population, the group actually eligible for today's standard of care. The market has largely priced the November approval as the ceiling for this asset — the August 17 decision would reset that.

✅ The Edge: First perioperative regimen in 25 years to beat cisplatin-based chemotherapy on both event-free and overall survival, not just one. Priority Review reflects how clean that EV-304 dataset looked at ASCO GU.

⚠️ The Risk: Grade 3+ adverse events ran 71% in the trial, and perioperative regimens require precise coordination between chemo cycles, surgery timing, and adjuvant dosing — any slippage in that sequencing, or surgeons defaulting back to familiar gem-cis, could blunt real-world uptake even after approval.

#9. OTLK — Outlook Therapeutics Inc.

THE CATALYST
Event: LYTENAVA (bevacizumab-vikg) / ONS-5010, NORSE EIGHT — PDUFA Regulatory Decision, Class 1 review, in wet age-related macular degeneration
Date: Jul 29, 2026
FDA Status: BTD
BSI: 5.80/10

Outlook won a Formal Dispute Resolution appeal after three prior CRLs, with the FDA agreeing that NORSE TWO plus NORSE EIGHT, natural-history, and mechanistic data together meet the evidentiary bar for approval — a rare reversal after that many rejections. The company's entire pipeline is one asset: an ophthalmic formulation of bevacizumab for retinal disease. It already launched in EU markets in 2025, partners with Cencora for U.S. logistics and pharmacovigilance, and continues seeking additional partners, including in China.

📈 The Setup: LYTENAVA is a VEGF inhibitor (an antibody that blocks the growth factor driving abnormal blood-vessel leakage in the eye) — chemically the same bevacizumab molecule doctors already use off-label as compounded Avastin, but manufactured and labeled specifically for ophthalmic use. NORSE TWO, the pivotal trial, met its primary endpoint outright; NORSE EIGHT then showed non-inferiority against ranibizumab (Lucentis) on vision-acuity change at eight weeks in treatment-naive patients. The FDA rejected that package three times before the appeal win forced the agency to accept it as sufficient. Eylea, Lucentis, and Vabysmo are the approved branded options; off-label compounded Avastin is the informal fourth option this drug is actually built to replace with an on-label, quality-controlled version. A Class 1 review — the fastest resubmission track — means a binary outcome inside three weeks.

✅ The Edge: Would be the first FDA-approved on-label ophthalmic bevacizumab, with 12 years of exclusivity attached. NICE has already recommended it in England and Wales as a cost-comparable alternative to Eylea — a template for U.S. payer conversations.

⚠️ The Risk: Three prior CRLs all cited insufficient confirmatory efficacy data — the exact category this Class 1 review has to get right with no new deficiencies. Retina specialists and payers may also just keep prescribing cheaper compounded Avastin even if this gets approved.

#10. LNTH — Lantheus Holdings Inc.

THE CATALYST
Event: Florquinitau (MK-6240) in Alzheimer's disease
Date: Aug 13, 2026
BSI: 5.47/10

Lantheus is fielding a roughly $7 billion takeover approach from Curium even as it heads into its first tau PET tracer decision — corporate and regulatory catalysts landing in the same window. The company focuses on PET imaging radiopharmaceuticals for oncology and neurology, built out its amyloid-tau franchise via the 2025 Life Molecular Imaging acquisition (which brought the approved amyloid tracer Neuraceq), and divested its SPECT business earlier this year to concentrate on PET.

📈 The Setup: MK-6240 is an F-18 labeled PET ligand (a radioactive tracer that lights up on a brain scan) built to bind aggregated tau, the misfolded protein that forms neurofibrillary tangles in Alzheimer's. In head-to-head comparisons, it detected tau pathology in 15% of amyloid-positive but cognitively unimpaired participants versus just 6% for Tauvid (flortaucipir), the only currently approved tau tracer — more than double the pickup rate, with less off-target binding in areas like the basal ganglia that have muddied Tauvid readings. Two pivotal Phase 3 trials met co-primary sensitivity and specificity endpoints for detecting tangles in cognitively impaired patients. Pairing MK-6240 with Lantheus's already-approved amyloid tracer Neuraceq would give clinicians a matched amyloid-tau diagnostic pair from one supplier — useful as more anti-amyloid therapies need pre-treatment staging. The market's pricing in approval, but the Curium takeover interest suggests someone thinks this diagnostic franchise is worth more than the stock currently reflects.

✅ The Edge: Detects tau pathology at more than double Tauvid's rate in early, cognitively unimpaired patients, with less off-target noise. Paired with Neuraceq, Lantheus would own the only matched amyloid-tau PET franchise from a single supplier.

⚠️ The Risk: There's no head-to-head registrational trial against Tauvid — the comparative edge comes from separate study data, which FDA could view differently than a direct comparison. Agency precedent here has focused on advanced-pathology detection, and reimbursement will hinge on proving added value over blood-based tau biomarkers now entering the market.

WATCHLIST

#11. VTRS — Viatris Inc. [Women's Health]

Price: $16.70 | Cap: $19.4B | Cash: $2.21B | RSI: 58.8 | Momentum: 0.9%
MR-100A-01 — PDUFA in contraception (Jul 30, 2026)
BSI: 5.02/10

The Intel: MR-100A-01 roughly halves the estrogen dose versus standard combination patches like Xulane (35mcg ethinyl estradiol) while keeping once-weekly norelgestromin dosing — the pitch is fewer estrogen-related side effects without losing weekly-patch convenience over daily pills. This reads as an incremental reformulation of an established mechanism, not new clinical ground, and the modest scoring signals here reflect that: worth tracking into July 30, not positioning around.

The Strategist's Take

The standout this week is MRNA at BSI 7.65 — it's the only name with both a clean regulatory trajectory (post-refusal-to-file, unanimous VRBPAC) and genuinely differentiated data, and the market still hasn't fully priced the manufacturing edge mRNA has over legacy egg-based flu production. ALPMY (6.13) tells a similar quality-of-data story in oncology: EV-304 is a real 25-year-benchmark-breaking result, but sits lower because the immediate binary reward is a label expansion, not a first approval — a smaller re-rating even if it hits.

Two names deserve a caution flag beyond what their BSI implies. FDMT (6.76) is running into July 18 with a conference presentation, not a pivotal readout — the durability data is genuinely strong, but 4FRONT-1 topline is still the trade that matters. LNTH (5.47) is attractive on the tau-detection numbers, but there's no head-to-head trial against Tauvid backing the comparison, and the Curium bid adds a corporate-action variable that could resolve before or instead of the PDUFA outcome.

Worth noting for the record: this week's scanner data required two corrections before publication (see note below) — the kind of thing worth remembering when leaning on any single field from the raw feed without a second look, especially cash/runway figures on foreign-domiciled names and CRL history on companies running multiple late-stage gene-therapy programs.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Manual corrections this week:

ALPMY (Astellas) cash figure: The underlying feed showed $1.441 trillion in cash against a $23.8B market cap — a currency-conversion error (likely JPY reported without conversion to USD). Corrected to Astellas's actual FY2025 cash position of ¥281.6B (≈$1.9B USD). Runway is shown as N/A since the standard runway calculation isn't meaningful for a profitable major pharma in any case.
RARE (Ultragenyx) regulatory history: The underlying feed's text fields described DTX401 as having received a July 2025 CRL. That CRL belongs to a different Ultragenyx program, UX111 (Sanfilippo Syndrome) — DTX401 itself had a clean Priority Review submission with no CRL. The entry above has been rewritten to reflect the correct history.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: July 10, 2026